Welcome to GMP for pharmaceutical packaging materials

Starting from January 1, 2026, the GMP for pharmaceutical packaging materials (Appendix to Pharmaceutical Excipients and Appendix to Pharmaceutical Packaging Materials of the Good Manufacturing Practice for Pharmaceuticals (Revised in 2010)) will be officially implemented, and regulatory requirements will be fully upgraded. As a pharmaceutical packaging company that has long been practicing the GMP standard, Xinfuda has actively responded to policy changes on the basis of existing compliance and took the lead in launching the "GMP Upgrade for Pharmaceutical Packaging Materials" project, aiming to continuously improve the quality management level with higher standards.

Xinfuda always puts product quality and safety first and has established a complete quality management system. This upgrade project is a systematic optimization based on the requirements of the new regulations and the needs of high-quality development of enterprises, focusing on three key areas: In terms of hardware facilities, the company will re-evaluate and re-upgrade the existing production environment that meets the standards, especially focusing on key links such as the aseptic packaging production environment emphasized in the specifications; In terms of quality management system, relying on the existing GMP management foundation, introduce a professional consulting team to upgrade the system, further strengthen the quality control of the entire process from raw materials to finished products, and improve the product traceability mechanism; In terms of personnel capacity building, based on the existing training system, carry out more targeted quality management training, and continuously improve the team's professional capabilities through simulated audits and other methods.

As an important quality assurance link in the pharmaceutical industry chain, Xinfuda has always adhered to the development concept of "quality-based enterprise". This GMP upgrade is not only a necessary measure to actively respond to policy requirements, but also a vivid embodiment of the company's quality culture of "continuous improvement and pursuit of excellence". Through this systematic upgrade, we will further improve the quality management level on the basis of existing compliance, create value for customers with better products and services, and contribute to ensuring drug safety.